Dsm-firmenich Ag · EURONEXT:DSFIR
Dsm-firmenich — Investor Day (June 2024)
21 slides from Dsm-firmenich's investor day presentation, Jun 3, 2024
Slide 1: Capital Markets Day
PARIS, JUNE 3 , 2024 RD Capital Markets Day Dimitri de Vreeze CEO
Slide 2: Our journey towards bringing progress to life
DREAM Our journey towards bringing progress to life Accelerate Tune Focus Innovation and Merge Prioritization of Creation-led Dream Full focus on high growth, high growth, backed 2 iconic companies building a leading margin segments by science & Bringing progress coming together consumer with a cali
Slide 3: We have been operating in a challenging macro environment
MERGE We have been … and we took decisive operating in a and immediate actions challenging macro environment… Unprecedented dynamics Integration Vitamin Portfolio in vitamins acceleration transformation review High inflation environment Changing geopolitical dynamics Seamless operations Simpler ‘Go-
Slide 4: Following a strategic assessment, we concluded that ANH no longer fits within our portfolio
FOCUS Following a strategic assessment, we concluded that ANH no longer fits within our portfolio ANH ~ €3.5 bn Sales dsm-firmenich excl. ANH ~ €9 bn Sales Animal Nutrition Perfumery Taste, Health, and Health & Beauty Texture Nutrition & Health & Care Integrated, global leader with scale, unique por
Slide 5: ANH transaction in the course of 2025
FOCUS ANH transaction in the course of 2025. With ANH team focusing on delivering strong results 2024 H2 2025 H2 Preparation Phase 2 Transaction phase 2024 Feb • Develop operational separation blueprint • Complete sign-to-close, Announcement • Prepare first steps of separation subject to external fa
Slide 6: Macro-trends give rise to holistic well-being, fueling market opportunities
FOCUS Macro-trends give rise to holistic well-being, fueling market opportunities Increasing focus on Lifespan vitality 50% Driven by growing older population Of global consumers attribute (“>60s" from 12% to 22% by 2050) as well as by high importance to a healthy, younger population natural & clean
Slide 7: We are a Category of One
FOCUS We are a Category of One We bring We are innovators progress to life and creators in well-being Nutrition Health Beauty Desirable Essential Sustainable Fueled and backed by Science 6
Slide 8: Post separation, we will strengthen our leadership position in Nutrition, Health and Beauty
FOCUS Post separation, we will strengthen our leadership position in Nutrition, Health and Beauty Well-being Nutrition Health Beauty Fueled and backed by Science €9 bn 3 ~21,000 ~5% Sales Complementary BUs BUs Employees OSG CAGR1,2 ~20% ~7% 60 15 Adj. EBITDA margin2 Sales in R&D Countries Research h
Slide 9: We focus on high growth, high margin segments with proven capability to add value
TUNE We focus on high growth, high margin segments with proven capability to add value Bubble size: Indicative sales P&B TTH HNC Currently ANH High Accelerate Calibrated portfolio steering Grow Bovaer Petfood Veramaris Improve to Grow i-Health Deprioritize • Accelerated portfolio review Market growt
Slide 10: Each segment has a clear mandate for value creation
TUNE Each segment has a clear mandate for value creation Very High High Stable/ Neutral Low Market Right-to-Win Nr. of Distribution attractiveness (e.g. adj. EBITDA margin Mandate segments of sales (e.g. market growth) & capital efficiency) Accelerate growth, driven by creation and Accelerate 6 ~15%
Slide 11: We deprioritize several businesses across our portfolio
TUNE We deprioritize several businesses across our portfolio Non-differentiated Aroma Agro Yeast Marine Vitamins Ingredients Ingredients Extracts Lipids >€100 mn ~€170 mn ~€40 mn ~€120 mn ~€170 mn Total sales Organic Sales Growth Adj. EBITDA Margin >€600 mn Low growth ~10% 10
Slide 12: A focused group consisting of 3 complementary Business Units
TUNE A focused group consisting of 3 complementary Business Units dsm-firmenich, building a company with over €10 bn sales Perfumery & Beauty Taste, Texture & Health Health, Nutrition & Care 5-6% 22-24% 6-8% 21-23% 4-6% 21-23% Organic sales growth, mid-term Adj. EBITDA Margin, mid-term 11
Slide 13: We operate from a common, customer unique business model
ACCELERATE We operate from a common, customer unique business model Partnering together with our customers Sustainability as business driver Ingredients Ingredient toolbox Creation & Innovation Excellence in portfolio, quality-breadth Brief solutions and regulation Best in class customer intimacy, c
Slide 14: We partner with our customers to push the boundaries of what is possible
ACCELERATE We partner with our customers to push the boundaries of what is possible Innovation & Creation 4 focal Science & Research Platforms fueling innovation pipeline across Nutrition, Health & Beauty 1 Biotechnology 2 Microbiome 3 Receptor biology To develop impactful products & To enable the r
Slide 15: Sustainability as business driver and core responsibility
ACCELERATE Sustainability as business driver and core responsibility Empower people to thrive Fuel Nurture healthy lives well-being People. We bring Planet. progress Progress. to life Accelerate Conserve our climate planet's action resources Safeguard nature and biodiversity Together with customers
Slide 16: We continue to drive our sustainability leadership
ACCELERATE We continue to drive our sustainability leadership Aiming for best-in-class ESG performance with our own operations and maximum positive impact on people and planet, together with our customers & partners New progress commitments Engagement, DE&I and safety key elements to be launched of
Slide 17: Committed to our mid-term objectives
ACCELERATE Committed to our mid-term objectives • Mid-single digit percentage of organic sales growth moving to a 5-7% Sales range, supported by revenue synergies and innovations • Adjusted EBITDA margin moving to the 22-23% range, supported by Mid-Term EBITDA synergies and innovations Financial Obj
Slide 18: Our journey towards bringing progress to life
ACCELERATE Our journey towards bringing progress to life Accelerate Tune Focus Innovation and Merge Prioritization of Creation-led Dream Full focus on high growth, high growth, backed 2 iconic companies building a leading margin segments by science & Bringing progress coming together consumer with a
Slide 19: Accelerating growth as a Category of One
dsm-firmenich STRATEGY Accelerating growth as a Category of One Where? Why? How? What? In the right space We bring progress to life Unique business model Our mid-term targets The rise of holistic well-being We capture these as a We operate from a common, We have confidence in fuels new market opport
Slide 20: Forward-looking statements disclaimer
This presentation contains forward-looking statements with respect to dsm-firmenich’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions
Slide 21: We bring progress to life
We bring progress to life